Single-cell DNA sequencing for minimal residual disease (MRD) — the detection of residual malignant cells at 0.001% sensitivity following cancer therapy, enabling relapse prediction and treatment adaptation, representing 18% of clinical single-cell applications — creates the most commercially dynamic market segment, with the Single Cell Sequencing Market reflecting MRD monitoring as the premium growth commercial driver.

The clonal evolution tracking — the identification of therapy-resistant subclones through single-cell copy number variation (CNV) and mutation analysis, predicting relapse 6-12 months before clinical manifestation — demonstrates the predictive power. Mission Bio's Tapestri platform and 10x Genomics' CNV solutions detecting leukemic stem cells at 0.01% frequency in remission bone marrow validate the clinical sensitivity, with hematology-oncology programs incorporating scDNA-seq into post-transplant monitoring protocols.

Acute myeloid leukemia (AML) MRD — the single-cell identification of persistent pre-leukemic clones (DNMT3A, TET2, ASXL1 mutations) versus therapy-resistant leukemic blasts — creates the precision monitoring application. Distinguishing clonal hematopoiesis of indeterminate potential (CHIP) from residual disease prevents overtreatment, with scDNA-seq reducing false-positive MRD rates by 40% compared to bulk sequencing.

Solid tumor circulating tumor cell (CTC) analysis — the single-cell profiling of rare CTCs from blood, enabling non-invasive MRD monitoring for breast, prostate, and lung cancer — creates the liquid biopsy application. RareCyte, Menarini Silicon Biosystems, and Fluidigm platforms isolating and sequencing individual CTCs demonstrate the technical capability, with clinical validation studies showing 85% concordance between CTC single-cell profiles and metastatic tissue biopsies.

Do you think single-cell MRD monitoring will replace flow cytometry and bulk NGS as the standard for post-treatment surveillance, or will cost and throughput limitations restrict it to high-risk patients and clinical trials?

What single-cell platforms are used for MRD detection? MRD platforms: Mission Bio Tapestri (microfluidic droplet, DNA + protein, 10,000+ cells, targeted panels 50-500 amplicons, CNV + SNV, $300-500 per sample); 10x Genomics CNV (single-cell copy number variation, whole genome, 1,000-10,000 cells, $200-400); DLP+ (Direct Library Preparation, nanoliter volumes, 500-5,000 cells, low cost $50-100); Smart-seq2 (full-length, high sensitivity, 100-1,000 cells, research use, $200-400); flow cytometry (10-color, 1,000,000+ cells, protein markers, $50-100, lower resolution); bulk NGS (error-corrected sequencing, 0.01% sensitivity, $200-500, no clonal resolution); clinical validation (Tapestri: AML MRD, 0.01% sensitivity, 6-month relapse prediction; 10x: CNV MRD, solid tumors, research stage); selection criteria: sensitivity requirements, sample cellularity, mutation panel scope, turnaround time, cost, clinical validation status.

How does single-cell MRD compare to traditional MRD methods? MRD method comparison: flow cytometry (sensitivity 0.01-0.1%, protein markers, 4-6 hours, $50-100, widely available, no clonal information, operator-dependent); bulk NGS (sensitivity 0.001-0.01%, error-corrected, 5-7 days, $200-500, mutation tracking, no clonal resolution, requires prior tumor sequencing); single-cell DNA (sensitivity 0.001-0.01%, clonal architecture, 3-5 days, $300-500, resistant subclone identification, pre-leukemic vs. leukemic distinction); clinical utility (flow: standard for ALL, AML; bulk NGS: emerging standard for multiple myeloma, lymphoma; scDNA: clinical trials, high-risk patients, relapse prediction); prognostic value (scDNA MRD-positive: 80% relapse probability at 12 months; scDNA MRD-negative: <10% relapse probability); cost-effectiveness (scDNA adds $200-300 per test; prevents unnecessary transplant, enables early intervention, improves survival).